Recruitment

Recruitment Status
Terminated
Estimated Enrollment
16

Inclusion Criterias

BMI ≤ 25 kg/m2
BMI ≤ 25 kg/m2

Exclusion Criterias

lactation, pregnancy
current treatment with any anti-hypertensive treatment
lipid lowering therapy or systemic steroids
...
lactation, pregnancy
current treatment with any anti-hypertensive treatment
lipid lowering therapy or systemic steroids
Raynaud's disease
history of postprandial hypoglycaemia and dumping syndrome
established cardiovascular disease
established cerebrovascular disease
bariatric surgery
blood pressure ≥ 140/85 mmHg
current or past history of diabetes (HbA1C more or equal 45mmol/mol)
severe impairment of renalhepatic, thyroid or adrenocortical function
established vascular disease
significant weight change within the last 3 months

Summary

Conditions
Healthy Subjects
Type
Interventional
Design
  • Allocation: Randomized
  • Intervention Model: Crossover Assignment
  • Masking: Triple (Participant, Investigator, Outcomes Assessor)
  • Primary Purpose: Health Services Research

Participation Requirements

Age
Between 18 years and 70 years
Gender
Both males and females

Description

In addition to the glucose lowering effect, incretin based therapies have also an effect on the vascular system. Previous animal work and initial human studies suggest that incretins may be cardioprotective and act as vasodilators through opening of KATP channels. Initial evidence suggests that bene...

In addition to the glucose lowering effect, incretin based therapies have also an effect on the vascular system. Previous animal work and initial human studies suggest that incretins may be cardioprotective and act as vasodilators through opening of KATP channels. Initial evidence suggests that beneficial vascular effects of incretin modifying agents may be nullified by the co-current treatment of the sulfonylurea (SU) drug glibenclamide. The investigators hypothesis is that the GLP-1 and SUs may have conflicting effects on the KATP channels and thus vascular function. Interestingly the vascular actions of GLP-1 were not modified by a different treatment SUs called glimepiride, thereby raising the possibility that SUs differentially modulating the vascular actions of GLP-1 though this remains controversial.

Inclusion Criterias

BMI ≤ 25 kg/m2
BMI ≤ 25 kg/m2

Exclusion Criterias

lactation, pregnancy
current treatment with any anti-hypertensive treatment
lipid lowering therapy or systemic steroids
...
lactation, pregnancy
current treatment with any anti-hypertensive treatment
lipid lowering therapy or systemic steroids
Raynaud's disease
history of postprandial hypoglycaemia and dumping syndrome
established cardiovascular disease
established cerebrovascular disease
bariatric surgery
blood pressure ≥ 140/85 mmHg
current or past history of diabetes (HbA1C more or equal 45mmol/mol)
severe impairment of renalhepatic, thyroid or adrenocortical function
established vascular disease
significant weight change within the last 3 months

Locations

Exeter, EX25DW
Exeter, EX25DW

Tracking Information

NCT #
NCT01934816
Collaborators
University of Exeter
Investigators
  • Principal Investigator: Katarina Kos, FRCP, PhD University of Exeter
  • Katarina Kos, FRCP, PhD University of Exeter